Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

ABIOMED Company Profile (NASDAQ:ABMD)

Consensus Ratings for ABIOMED (NASDAQ:ABMD) (?)
Ratings Breakdown: 2 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $76.00 (19.78% upside)

Analysts' Ratings History for ABIOMED (NASDAQ:ABMD)
Show:
DateFirmActionRatingPrice TargetActions
5/9/2015Jefferies GroupReiterated RatingBuy$72.00 -> $83.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015BTIG ResearchReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Leerink SwannBoost Price TargetOutperform$72.00 -> $88.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Northland SecuritiesBoost Price TargetMarket Perform$40.00 -> $60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2015ZacksUpgradeHold -> Buy$73.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2015ZacksDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2015BTIG ResearchReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/23/2015ZacksReiterated RatingStrong-Buy -> Strong-Buy$69.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/17/2015Leerink SwannBoost Price TargetOutperform$60.00 -> $72.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2015ZacksReiterated RatingNeutral -> Neutral$54.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2015BTIG ResearchReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2015Leerink SwannBoost Price TargetOutperform$43.00 -> $60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2015Northland SecuritiesUpgradeUnder Perform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2015Jefferies GroupReiterated RatingBuy$45.00 -> $56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/5/2015Jefferies GroupReiterated RatingBuy$37.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/20/2014ZacksReiterated RatingNeutral -> Neutral$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2014TheStreetUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/3/2014BTIG ResearchDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/5/2014ZacksReiterated RatingNeutral -> Neutral$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2014Leerink SwannInitiated CoverageOutperform$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/21/2014BTIG ResearchUpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/20/2014BTIG ResearchInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/10/2014WunderlichBoost Price TargetBuy$29.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2013Benchmark Co.Reiterated RatingBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2013Northland SecuritiesBoost Price TargetUnderperform$9.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2013Jefferies GroupBoost Price TargetBuy$25.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/1/2013Benchmark Co.Initiated CoverageSpeculative Buy -> Buy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/11/2013TheStreetUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/25/2013 forward)